{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T20:15:42Z","timestamp":1774383342689,"version":"3.50.1"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Mucormycosis is a highly invasive and rare opportunistic infection caused by mucor fungi, characterized by challenging diagnosis and rapid disease progression. It predominantly affects patients with compromised immune systems due to various reasons, such as kidney failure, long-term use of antibiotics or corticosteroids. We recently successfully treated a pediatric patient with rapidly progressive glomerulonephritis accompanied by severe cutaneous mucormycosis. To our knowledge, this is the first reported case of rapidly progressive glomerulonephritis nephritis accompanied by dermatophytosis in a pediatric patient. In this case, we share our management experience, including special nursing experience. Cutaneous mucormycosis progresses quickly and is difficult to diagnose and treat, especially in children with compromised immune function, warranting high vigilance from clinicians and nursing staff. Early diagnosis and targeted treatment are crucial for improving the prognosis of patients. Therefore, once there is a suspicion of a mucormycosis infection, we recommend the early application of various testing methods such as fungal culture, skin biopsy and genetic testing in order to to promptly confirm the diagnosis.<\/jats:p>","DOI":"10.3389\/fped.2025.1484145","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T04:13:00Z","timestamp":1746677580000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of a pediatric patient with rapidly progressive glomerulonephritis and cutaneous mucormycosis: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Lili","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaili","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.12669\/pjms.38.ICON-2022.5774","article-title":"Rapidly progressive glomerulonephritis in children","volume":"38","author":"Moorani","year":"2022","journal-title":"Pak J Med Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11046-021-00607-4","article-title":"Mucormycosis in Mainland China: a systematic review of case reports","volume":"187","author":"Wei","year":"2022","journal-title":"Mycopathologia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"101007","DOI":"10.1016\/j.mycmed.2020.101007","article-title":"Mucormycosis treatment: recommendations, latest advances, and perspectives","volume":"30","author":"Brunet","year":"2020","journal-title":"J Mycol Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/jpids\/pix107","article-title":"Mucormycosis in children: review and recommendations for management","volume":"7","author":"Francis","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/cid\/cir866","article-title":"Epidemiology and clinical manifestations of mucormycosis","volume":"54","author":"Petrikkos","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/1469-0691.12466","article-title":"Why is mucormycosis more difficult to cure than more common mycoses?","volume":"20","author":"Katragkou","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","article-title":"Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) working group on zygomycosis between 2005 and 2007","volume":"17","author":"Skiada","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"B8","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jmii.2022.12.004","article-title":"COVID-19 associated mold infections: review of COVID-19 associated pulmonary aspergillosis and mucormycosis","volume":"56","author":"Huang","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1093\/jac\/dkv236","article-title":"Prospective pilot study of high-dose (10\u2005mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis","volume":"70","author":"Lanternier","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"B12","doi-asserted-by":"publisher","first-page":"115010","DOI":"10.1016\/j.ejmech.2022.115010","article-title":"Mucormycosis: a hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents","volume":"246","author":"Hussain","year":"2023","journal-title":"Eur J Med Chem"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1484145\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T04:13:00Z","timestamp":1746677580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1484145\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":12,"alternative-id":["10.3389\/fped.2025.1484145"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1484145","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"article-number":"1484145"}}